Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

A new clinical trial from Scripps Research in La Jolla aims to make significant gains in the global fight against malaria by ...

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...

Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application ...

Gilead (GILD) announced that the European Medicines Agency has validated for parallel accelerated review the company’s marketing authorization ...

The EMA is set to perform accelerated reviews of Gilead Sciences’ applications for its twice-yearly injectable for HIV ...

This was the stock's third consecutive day of gains.

Lenacapavir is already approved under the name Sunlenca as an HIV treatment for patients resistant to other medication ...

Wrestling sectionals were held over the weekend and Marion-area competitors earned berths into the upcoming district ...

CompanyOverview|NASDAQ:GILD] Gilead Sciences Inc. (NASDAQ: GILD) stock surged to a new 52-week high at $106.69 recently on ...

A groundbreaking injectable designed to curb the global spread of HIV is now at risk of being delayed due to Donald Trump's ...

Learn more about whether Gilead Sciences, Inc. or Insmed Incorporated is a better investment based on AAII's A+ Investor ...